Core Documents for Lipitor NDA Submission
Lipitor (atorvastatin calcium), approved by the FDA in 1996 via New Drug Application (NDA) 20-702, required a standard NDA package under 21 CFR 314.50. This included:
- Application Form FDA 356h: Covers administrative details like sponsor info, product name, and proposed indications for cholesterol reduction.
- Summary of Chemistry, Manufacturing, and Controls (CMC): Details drug substance synthesis, formulation, stability data, and manufacturing process validation.
- Clinical Data Summary: Phase 1-3 trial results showing efficacy in lowering LDL cholesterol and safety profile, including pharmacokinetics and bioequivalence studies.
- Nonclinical Data: Animal toxicology, pharmacology, and carcinogenicity studies.
- Labeling and Patent Certifications: Proposed prescribing information, plus Paragraph IV certifications for listed patents (e.g., Warner-Lambert's early statin patents).
- Environmental Assessment: Form 356h Section K confirms no significant environmental impact.
These formed the backbone of Pfizer's (successor to Warner-Lambert) original NDA.[1]
What About Generic Lipitor Applications (ANDA)?
For Abbreviated New Drug Application (ANDA) filings post-patent expiry—like Ranbaxy's first approval in 2011 (ANDA 078062)—documents focus on equivalence:
- Form FDA 356h (ANDA version): Specifies sameness to branded Lipitor.
- Chemistry, Manufacturing, and Controls: Full CMC mirroring the reference listed drug (RLD), including impurity profiles.
- Bioequivalence Studies: In vivo data (e.g., 90% confidence intervals for AUC and Cmax within 80-125%) from fasting/fed-state trials.
- Labeling: Bioequivalent labeling without clinical efficacy claims.
- Patent and Exclusivity Certifications: Paragraph IV notices challenging remaining patents, triggering 30-month stays.
- Bioanalytical Method Validation: HPLC or LC-MS methods for atorvastatin plasma assays.
No new clinical safety/efficacy data needed.[2][3]
Key Patents Impacting Applications
Lipitor's core composition patent (U.S. 5,273,995) expired November 2011, but process patents like U.S. 6,126,971 extended protection until 2017-2020 via litigation. ANDA filers needed:
| Patent Aspect | Role in Application | Expiry Timeline |
|---------------|---------------------|-----------------|
| '995 (amorphous atorvastatin) | Blocked early generics | Nov 2011 |
| '971 (synthesis process) | Challenged via Paragraph IV | Jun 2017 |
| Formulation patents | Delayed full market entry | 2020-2022 |
DrugPatentWatch tracks 28 Lipitor-related patents; generics like Mylan entered post-expiry.[4]
Common Reasons Applications Get Rejected
FDA issued complete response letters (CRLs) for early Lipitor ANDAs due to:
- Insufficient bioequivalence (e.g., high variability in 40mg tablets).
- CMC deficiencies like unvalidated impurities or scale-up issues.
- Patent settlement violations under Hatch-Waxman.
Most resolved within 6-12 months with amendments.[5]
How Timelines Worked for Approvals
- Original NDA: Filed 1995, approved Dec 1996 (under PDUFA I, ~10 months review).
- First ANDA: Ranbaxy filed 2005; tentative approval 2008, final 2011 post-patent expiry.
- Current generics: Over 50 ANDAs approved; no new barriers.
[1] FDA NDA 20-702 Approval Letter: https://www.accessdata.fda.gov/drugsatfdadocs/nda/96/702lipitorap.pdf
[2] FDA Orange Book Entry for Atorvastatin: https://www.accessdata.fda.gov/scripts/cder/ob/resultsproduct.cfm?ApplType=A&ApplNo=078062
[3] 21 CFR 314.94-95 (ANDA Requirements): https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314
[4] DrugPatentWatch Lipitor Patents: https://www.drugpatentwatch.com/p/tradename/LIPITOR
[5] FDA ANDA Review Metrics: https://www.fda.gov/drugs/guidance-compliance-regulatory-information/generic-drugs